ClinicalTrials.gg
Not yet recruitingNCT07721233Updated Jul 23, 2026

Virtual-reality Induced Immune Modulation in Allergic Patients

An interventional study of Allergen-related immersive virtual reality exposure and Control immersive virtual reality exposure in Hymenoptera Venom Allergy, sponsored by University of Geneva, Switzerland. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by University of Geneva, Switzerland · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study investigates whether immersive virtual reality (VR) exposure to allergen-related stimuli can modulate behavioural, neurophysiological, psychophysiological, and immune responses in adults with bee or wasp venom allergy.

The study consists of two parts. In Part 1, adults with documented bee or wasp venom allergy and healthy volunteers will undergo immersive VR exposure in a realistic picnic environment. All participants will first be exposed to a control condition involving virtual flies. They will then be randomly assigned to exposure to either virtual bees or wasps or a control condition involving virtual flies. During the VR sessions, behavioural responses, heart rate and heart-rate variability, skin conductance, pupil dilation, temperature, and electroencephalographic activity will be recorded. Blood samples will be collected before and after VR exposure to assess changes in basophil activation and other immunological markers.

In Part 2, patients receiving standard-of-care venom immunotherapy will be followed longitudinally. Blood samples will be collected before and during treatment to characterize immunological changes associated with venom desensitization. After approximately six months of venom immunotherapy, participants will undergo a further VR session involving either virtual bees or wasps or virtual flies. Behavioural, psychophysiological, neurophysiological, and immunological assessments will be repeated to determine whether venom immunotherapy reduces responses to virtual allergen-related stimuli.

The primary outcome is the change in basophil activation, measured as the percentage of CD63-positive circulating basophils. Secondary outcomes include changes in circulating type 2 innate lymphoid cells and regulatory T cells, serum IL-13 and tryptase concentrations, reaction times, cardiovascular and autonomic responses, pupil dilation, skin temperature, and electroencephalographic responses.

The study does not involve exposure to real insects or venom as part of the investigational VR procedure. Its aim is to improve understanding of brain-immune interactions in allergy and to provide preliminary evidence for the potential future use of VR-based approaches alongside conventional allergy treatment.

02

Conditions studied

  • Hymenoptera Venom Allergy

Keywords

  • Virtual Reality
  • Neuroimmune Interaction
  • Immune Modulation
  • Basophil Activation
  • Venom Immunotherapy
  • Bee Venom
  • Wasp Venom
03

In context

Lead sponsor

University of Geneva, Switzerland is the lead sponsor of 43 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Able to understand the participant information and provide written .
  • Willing and able to comply with all study procedures.

Part 1 - Healthy volunteers

  • No known bee or wasp venom allergy.
  • No current allergen immunotherapy or monoclonal antibody treatment.
  • No known active allergic, , inflammatory, or immunodeficiency disorder requiring systemic treatment.

Part 1 - Participants with bee or wasp venom allergy

  • Documented bee and/or wasp venom allergy based on medical history and/or routine allergy work-up.
  • No ongoing venom immunotherapy at the time of inclusion in Part 1.
  • No current monoclonal antibody treatment or systemic treatment at the time of testing.

Part 2 - Participants undergoing venom immunotherapy

  • Documented bee and/or wasp venom allergy based on medical history and/or routine allergy work-up.
  • Planned initiation of or ongoing treatment with standard-of-care venom immunotherapy.

Exclusion criteria

Exclusion Criteria

  • Absence of written .
  • Inability to understand the study information or provide informed consent.
  • Age younger than 18 years.
  • Current systemic therapy.
  • Current monoclonal antibody treatment for an allergic, , or inflammatory disease at the time of testing.
  • Ongoing allergen immunotherapy for allergies other than bee or wasp venom allergy.
  • Leukocyte count below 3.5 G/L.
  • below approximately 120 g/L in women or below approximately 130 g/L in men.
  • Bee or wasp sting reaction within the previous 2 months.
  • Intolerance to virtual reality, as assessed during a preliminary interview
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
81 participants (estimated)

Study arms

  • Experimental
    Part 1: Allergen-related VR exposure

    Behavioral: Allergen-related immersive virtual reality exposure · Behavioral: Control immersive virtual reality exposure

  • Sham comparator
    Part 1: Control VR exposure

    Behavioral: Control immersive virtual reality exposure

  • Experimental
    Part 2: Allergen-related VR exposure during VIT

    Behavioral: Allergen-related immersive virtual reality exposure

  • Sham comparator
    Part 2: Control VR exposure during VIT

    Behavioral: Control immersive virtual reality exposure

Interventions

  • BehavioralAllergen-related immersive virtual reality exposure

    Participants undergo an immersive virtual reality session in a realistic multisensory environment. Virtual bees or wasps progressively approach the participant and ultimately land on the participant's hand. Visual, auditory, and haptic stimuli are presented, and a brief stimulus is delivered to simulate a sting.

  • BehavioralControl immersive virtual reality exposure

    Participants undergo an immersive virtual reality session in a realistic multisensory environment. Virtual flies progressively approach the participant and ultimately land on the participant's hand. Visual, auditory, and haptic stimuli are presented, and a brief synchronized stimulus is delivered to simulate touch or tickling. In Part 1, this intervention is administered to all participants as the initial baseline exposure and is repeated in participants assigned to the control condition.

06

What researchers measure

Primary outcomes

  1. Change in Percentage of CD63-Positive Circulating Basophils Following Virtual-Reality Exposure in Part 1

    Time frame: T0, 10 minutes after the initial fly exposure, to T2, 40 minutes after the second VR exposure; same study day

  2. Change in Percentage of CD63-Positive Circulating Basophils During Venom Immunotherapy and Subsequent Virtual-Reality Exposure in Part 2

    Time frame: Before initiation of venom immunotherapy at T0 to 40 minutes after VR exposure at approximately month 7 at T5

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — The protocol states that raw individual-level results will not be shared with third parties and that study results will be presented only in aggregated, non-identifiable form. This does not prevent publication of aggregate results or deposition of summary datasets that contain no participant-level information.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Oct 2030, 47 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 23, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Oct 2030
CompletionEst.
Oct 2030
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07721233
Lead sponsor
University of Geneva, Switzerland
Responsible party
Peter Jandus (PD Dr. med., University of Geneva, Switzerland) — Principal investigator
First posted
Jul 23, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Oct 2030 (estimated)
Completion
Oct 2030 (estimated)
Last update
Jul 23, 2026

Study contacts

Peter Jandus
Contact
peter.jandus@hug.ch
+41 22 372 93 82
Camilla Jandus
Contact
camilla.jandus@unige.ch
+41 22 379 54 40

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion